Itay Raphael retweeted
What comes after M1/M2? In our Perspective with @FGinhoux in @ImmunityCP we explore how single-cell technologies and AI can decode the gene programs macrophages use across tissues & microenvironments, and how this modular view could transform immunotherapy
cell.com/immunity/abstract/S…
Itay Raphael retweeted
Intratumoral T cell activation kills tumors regardless of T cell specificity @NatImmunol @oliviacs_ @umnmstp
@masopust_vezys @cfi_umn @Noah_V_Gavil
nature.com/articles/s41590-0…
Itay Raphael retweeted
Cancer drug response and resistance: molecular mechanisms and combating strategies
nature.com/articles/s41392-0…
Itay Raphael retweeted
Highlighting Understudied Inflammatory Diseases: Congratulations to Itay Raphael, Zuckerman faculty scholar on the publication of Exploring Understudied Inflammatory Diseases, in the journal Expert Review of Clinical Immunology. Defined as medical conditions with limited or insufficient research, inadequate funding and the need for more clinical trials, the editorial highlights how understanding the genetic and molecular mechanisms of these conditions could improve diagnosis and treatment of immunological diseases @HebrewU_heb tandfonline.com/doi/epdf/10.…
Itay Raphael retweeted
New Faculty Scholars Choose to Return to Israel. @itay_raphael @HebrewU_heb @HebrewU
Itay Raphael studies the complexities of the immune system, with the aim of translating his findings into clinical impact. He earned his doctorate in Cell and Molecular Biology from the University of Texas at San Antonio, where he examined the role of T cells in neuroinflammatory diseases, such as multiple sclerosis.
Dr. Raphael subsequently pursued postdoctoral research at the University of Pittsburgh School of Medicine, where he was awarded a National Institutes of Health training fellowship in Immunology and Immunopathology to investigate immunoregulatory mechanisms of T cells in neuroinflammation. This was the first of several prestigious grants he received.
At the University of Pittsburgh, a faculty mentor sparked Dr. Raphael’s interest in developing novel therapeutics for aggressive childhood glioma, a form of brain cancer. Their collaborative work integrated cancer immunology, computational biology, and neuro-oncology, leading to clinical trials at the university’s UPMC Hillman Cancer Center. Ultimately, his contributions led to his promotion to Research Assistant Professor in the Department of Neurological Surgery at the University of Pittsburgh.
Now back in Israel where he grew up, Dr. Raphael is an Assistant Professor (Senior Lecturer) at the Institute for Drug Research in the School of Pharmacy, part of the Faculty of Medicine at The Hebrew University of Jerusalem. In his newly established laboratory, he focuses on brain cancer immunology and T cell immunotherapies. Recognizing that few patients with brain tumors currently benefit from recent advances in cancer immunotherapy, his research seeks to uncover the immunoregulatory mechanisms of T cells in brain tumors, with the aim of identifying and evaluating innovative immunotherapeutic strategies that have the potential to serve as life-saving treatments for both pediatric and adult patients. He is committed to helping ensure that Israel remains a global leader in cellular immunology and innovative translational research.
zuckermanstem.org/scholars/d…
Excited to share our new paper in @CMI_Journal.
We’ve identified a mechanism driving #GBM progression that also creates a targetable antigen from RCAN1 alternative splicing, and developed novel RCAN1-specific T cells with high efficacy. lnkd.in/eD9DrAcZ
Itay Raphael retweeted
Congrats Gary et al. @PittNeurosurg POSTN is an extracellular matrix protein strongly associated with inflammatory 'mesenchymal' subtypes of GBM, and as we found over a decade ago, associated with peritumoral FLAIR signal in GBM. Even KD and overexpression recapitulated these MRI phenotypes in a mouse model. Always wondered whether POSTN was an important marker in GBM, despite being relatively downstream. journals.plos.org/plosone/ar… aacrjournals.org/clincancerr…
Study identifies promising source of new antigen targets—derived from glioma expressed isoforms—for the development of immunotherapies for patients with brain tumors. nature.com/articles/s41435-0… @UPMCHillmanCC @BashBrainTumors
From TCRs to immunotherapy targets: detection of antigens in pediatric brain tumors acir.org/weekly-digests/2025…
Classifying childhood brain cancers by immune response may improve diagnostics and treatments, via @EurekAlert! eurekalert.org/news-releases…
Itay Raphael retweeted
Fantastic study! Congratulations Itay, Gary and Ian!!!
Researchers and pediatric neurosurgeons at @pitt_medicine and @ChildrensPgh have developed a new way to profile brain cancers in children, paving the way for improved diagnostics and treatments. science.org/doi/10.1126/scit… @BashBrainTumors @itay_raphael @UPMC @ScienceMagazine
Researchers Predict Paradigm Shift in the Analysis of TILs in Pediatric Brain Tumors insideprecisionmedicine.com/… via @Inside_PM
Researchers Predict Paradigm Shift in the Analysis of TILs in Pediatric Brain Tumors insideprecisionmedicine.com/… via @Inside_PM
Itay Raphael retweeted
.@jitcancer article explores recent findings and provides perspective on the complexity of how some immunotherapy may be effective for melanoma brain metastases. jitc.bmj.com/content/13/3/e0… @BashBrainTumors @Steve_Frederico @UPMCHillmanCC
Itay Raphael retweeted
Researchers identify immune system related genes (HLA alleles) linked with brain cancer risk in the population and patient outcomes. May start to answer the question why patients get brain tumors. academic.oup.com/neuro-oncol… @BashBrainTumors @hadjiMDPhD @UPMCPhysicianEd @NeuroOnc
















